What are the Historical Developments and Current Growth Metrics of the Eosinophilic Asthma Market?
The eosinophilic asthma market has seen considerable growth due to a variety of factors.
• In recent times, we have seen a fast-paced escalation in the market size for eosinophilic asthma. The market projection suggests an increase from $2.69 billion in 2024, escalating to a value of $3.17 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.7%.
This significant growth over the historical period can be ascribed to several contributing factors, including amplified pollution levels, a decline in population immunity, a higher incidence of eosinophilic asthma, an increase in the prevalence of allergens and respiratory conditions, escalating healthcare spending, and a surge in R&D endeavours.
What is the Forecasted Market Size and CAGR for the Eosinophilic Asthma Market?
The eosinophilic asthma market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, a swift expansion is anticipated in the eosinophilic asthma market, which is projected to surge to $6.01 billion by 2029, growing at a compound annual growth rate (CAGR) of 17.4%.
The predicted growth in this duration can be linked to the escalating prevalence of respiratory illnesses, heightened consciousness and diagnosis rates, broadening usage of monoclonal antibodies, increased healthcare infrastructure investments, and the surge in personalised medication strategies. The forecast period is likely to see significant trends such as the creation of targeted biologics, advanced diagnostic tools, bespoke treatment procedures, bettered drug delivery systems, the incorporation of digital health technologies, and wide-ranging clinical trials for innovative therapies.
What Key Factors and Trends Are Driving The Growth Eosinophilic Asthma Market?
The escalation in smoking tendencies is projected to spur the expansion of the eosinophilic asthma market in future. Smoking tendencies essentially mean the persistent actions or habits associated with tobacco usage, including frequency, context, and duration of smoking, often governed by psychological, social and environmental influences. The amplification in smoking tendencies can be attributed to factors such as heightened stress levels, targeted promotions by tobacco corporations, ignorance regarding health repercussions, and social validation for smoking in some cultures. Eosinophilic asthma treatment aids in lowering inflammation in the airways and enhancing lung function, which can foster smoking cessation by mitigating the respiratory distress that usually compels patients to continue smoking. For example, in December 2023, as per the National Health Service, a government department in the UK, around 408,700 hospitalizations were reported in 2022–23 due to smoking, an escalation from 389,800 in 2021–22, marking a 4.8% increase. Hence, the elevation in smoking rates propels the eosinophilic asthma market.
What Are The Market Segments In The Eosinophilic Asthma Market?
The eosinophilic asthma market covered in this report is segmented –
1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma
2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma
2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma
Pre-Book The Eosinophilic Asthma Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Eosinophilic Asthma Market?
Leading entities operating in the eosinophilic asthma market are evolving with groundbreaking medications that focus on well-defined immune pathways, curbing inflammation, and refining patient results with customised treatment choices. A type of molecule produced in the laboratory, monoclonal antibodies, can mirror the immune response against harmful intruders like bacteria and viruses. These are produced via a method combining a particular antibody-producing cell with a cancer cell, yielding a vast supply of exact replicas of antibodies on a large scale. For example, in August 2024, AstraZeneca plc, a British biopharmaceutical firm, reported Fasenra was greenlit by the National Medical Products Association in China, a state-run body, for treating severe eosinophilic asthma. The medication is aimed specifically at patients suffering from severe eosinophilic asthma; a disorder typified by heightened eosinophil levels, potentially resulting in inflammation and deterioration of asthma symptoms. The medication is a monoclonal antibody that focuses on and diminishes eosinophils utilising a distinct mechanism. Fasenra bolsters the immune response by adhering to the IL-5 receptor on eosinophils, to suppress eosinophil levels in blood and tissues. The dosage regimen commences with a loading phase subsequently followed by maintenance doses. Generally, patients are given injections every four weeks for the initial three doses, and thereafter every eight weeks.
Who Are the Key Players In The Eosinophilic Asthma Market?
Major companies operating in the eosinophilic asthma market are:
• Roche Holding AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• GSK plc
• Amgen Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Limited
• Boehringer Ingelheim GmbH
• Regeneron Pharmaceuticals Inc.
• Chiesi Farmaceutici S.p.A.
What Are The Regional Insights Into The Eosinophilic Asthma Market?
North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
